Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ioversol
Drug ID BADD_D01186
Description Ioversol is classified as an _organoiodine_ compound and is used as a contrast dye in diagnostic procedures. It contains high levels of iodine in addition to various hydrophilic groups.
Indications and Usage Optiray 350 is indicated in adults for peripheral and coronary arteriography and left ventriculography. Optiray 350 is also indicated for contrast enhanced computed tomographic imaging of the head and body, intravenous excretory urography, intravenous digital subtraction angiography and venography. Optiray 350 is indicated in children for angiocardiography. Optiray 320 is indicated in adults for angiography throughout the cardiovascular system. The uses include cerebral, coronary, peripheral, visceral and renal arteriography, venography, aortography, and left ventriculography. Optiray 320 is also indicated for contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography. Optiray 320 is indicated in children for angiocardiography, contrast enhanced computed tomographic imaging of the head and body, and intravenous excretory urography. Optiray 300 is indicated for cerebral angiography and peripheral arteriography. Optiray 300 is also indicated for contrast enhanced computed tomographic imaging of the head and body, venography, and intravenous excretory urography. Optiray 240 is indicated for cerebral angiography and venography. Optiray 240 is also indicated for contrast enhanced computed tomographic imaging of the head and body and intravenous excretory urography.
Marketing Status approved
ATC Code V08AB07
DrugBank ID DB09134
KEGG ID D01555
MeSH ID C054871
PubChem ID 3741
TTD Drug ID D0U1ZD
NDC Product Code 0019-1323; 0019-1332; 0406-7888; 0019-1333; 57884-0015; 67684-8777
UNII N3RIB7X24K
Synonyms ioversol | Optiray 320 | Optiray | Optiray 300
Chemical Information
Molecular Formula C18H24I3N3O9
CAS Registry Number 87771-40-2
SMILES C(CO)N(C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I)C(=O)CO
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Eye irritation06.04.05.0030.019206%Not Available
Eye swelling06.08.03.0030.189927%Not Available
Eyelid oedema23.04.01.003; 10.01.05.001; 06.04.04.0040.098876%Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.0030.087495%
Feeling abnormal08.01.09.014--Not Available
Feeling cold08.01.09.0080.017783%Not Available
Feeling hot08.01.09.0090.093185%Not Available
Flushing23.06.05.003; 08.01.03.025; 24.03.01.0020.140134%
Gangrene24.04.05.003; 23.06.06.001; 11.02.01.003--Not Available
Generalised tonic-clonic seizure17.12.01.0020.007113%Not Available
Haematoma24.07.01.001--
Haematuria21.10.01.018; 24.07.01.047; 20.02.01.006--
Haemoglobin13.01.05.018--Not Available
Hallucination19.10.04.003--
Hallucination, visual19.10.04.007--Not Available
Headache17.14.01.001--
Hemiparesis17.01.04.001--
Hemiplegia17.01.04.002--Not Available
Hepatorenal syndrome09.01.03.007; 20.01.03.012--Not Available
Hyperaemia24.03.02.0020.010670%Not Available
Hyperhidrosis23.02.03.004; 08.01.03.0280.102433%
Hypersensitivity10.01.03.0030.347133%
Hypertension24.08.02.0010.081093%
Hypertensive crisis24.08.01.001--Not Available
Hyperthermia12.05.01.002; 08.05.01.0010.007113%Not Available
Hyperventilation22.02.01.006; 19.01.02.0040.007113%Not Available
Hypoaesthesia23.03.03.081; 17.02.06.0230.110258%Not Available
Hypotension24.06.03.0020.109546%
Hypothermia12.05.03.001; 08.05.01.0030.007113%
Hypotonia17.05.02.002; 15.05.04.0080.007113%Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 10 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene